Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.16B |
| 2 |
Bank of America
BAC
|
+$855M |
| 3 |
Comcast
CMCSA
|
+$620M |
| 4 |
Amazon
AMZN
|
+$505M |
| 5 |
Micron Technology
MU
|
+$486M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Goldman Sachs
GS
|
+$441M |
| 2 |
Palo Alto Networks
PANW
|
+$300M |
| 3 |
Verizon
VZ
|
+$286M |
| 4 |
Fidelity National Information Services
FIS
|
+$285M |
| 5 |
Stanley Black & Decker
SWK
|
+$244M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 6.22% |
| 2 | Financials | 6.16% |
| 3 | Industrials | 5.09% |
| 4 | Consumer Discretionary | 4.89% |
| 5 | Healthcare | 4.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
5126
CALL
Vanguard Morningstar Growth ETF
VUG
$230B
| $647K | ﹤0.01% |
27,600
+6,000
| +28% | +$138K |
|
|
APU
5127
PUT
DELISTED
AmeriGas Partners, L.P.
APU
| $647K | ﹤0.01% |
+14,000
| New | +$630K |
|
|
ZNGA
5128
PUT
DELISTED
ZYNGA INC. CL A COMMON
ZNGA
| $646K | ﹤0.01% |
161,500
+21,400
| +15% | +$83.4K |
|
|
GNBC
5129
DELISTED
Green Bancorp, Inc
GNBC
| $646K | ﹤0.01% |
31,827
-127
| -0.4% | -$2.82K |
|
|
WLH
5130
CALL
DELISTED
WILLIAM LYON HOMES
WLH
| $646K | ﹤0.01% |
22,200
+100
| +0.5% | +$2.71K |
|
5131
PUT
EPAM Systems
EPAM
$5.18B
| $645K | ﹤0.01% |
6,000
+3,200
| +114% | +$317K |
|
5132
PUT
Alaunos Therapeutics
TCRT
$4.71M
| $645K | ﹤0.01% |
1,039
+217
| +26% | +$156K |
|
5133
CALL
iShares US Basic Materials ETF
IYM
$1.02B
| $644K | ﹤0.01% |
6,300
+800
| +15% | +$79.4K |
|
5134
Corcept Therapeutics
CORT
$12.4B
| $643K | ﹤0.01% |
35,576
-96,260
| -73% | -$1.74M |
|
5135
Aegon
AEG
$14B
| $642K | ﹤0.01% |
125,222
+47,258
| +61% | +$230K |
|
5136
CALL
First Trust Health Care AlphaDEX Fund
FXH
$1.11B
| $642K | ﹤0.01% |
+9,200
| New | +$628K |
|
|
SPPI
5137
PUT
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $642K | ﹤0.01% |
+33,900
| New | +$614K |
|
|
MCRN
5138
DELISTED
Milacron Holdings Corp.
MCRN
| $642K | ﹤0.01% |
33,544
-223,346
| -87% | -$3.99M |
|
|
EGC
5139
DELISTED
Energy XXI Gulf Coast, Inc. Common Stock
EGC
| $642K | ﹤0.01% |
111,792
-1,033
| -0.9% | -$7.27K |
|
5140
PUT
Amphenol
APH
$206B
| $641K | ﹤0.01% |
29,200
+14,000
| +92% | +$308K |
|
5141
PUT
Franklin Covey
FC
$229M
| $641K | ﹤0.01% |
30,900
+10,700
| +53% | +$210K |
|
5142
PJT Partners
PJT
$4.46B
| $641K | ﹤0.01% |
+14,064
| New | +$572K |
|
5143
CALL
Shutterstock
SSTK
$210M
| $641K | ﹤0.01% |
+14,900
| New | +$581K |
|
5144
CALL
Novanta
NOVT
$6.3B
| $640K | ﹤0.01% |
12,800
-100
| -0.8% | -$4.87K |
|
|
ESGF
5145
DELISTED
Oppenheimer Global ESG Revenue ETF
ESGF
| $640K | ﹤0.01% |
+20,403
| New | +$640K |
|
5146
IDT Corp
IDT
$1.66B
| $639K | ﹤0.01% |
71,237
+18,279
| +35% | +$200K |
|
5147
PUT
Sensata Technologies
ST
$6.73B
| $639K | ﹤0.01% |
+12,500
| New | +$616K |
|
5148
Invesco S&P 500 High Dividend Low Volatility ETF
SPHD
$3.44B
| $638K | ﹤0.01% |
15,038
-8,203
| -35% | -$344K |
|
5149
UDR
UDR
$12.2B
| $638K | ﹤0.01% |
16,570
-206,897
| -93% | -$8.04M |
|
|
TBRG
5150
DELISTED
TruBridge
TBRG
| $638K | ﹤0.01% |
21,243
+6,533
| +44% | +$194K |
|
Similar funds
Ken Griffin's Q4 2017 Portfolio in Review
As of Q4 2017, Ken Griffin held 8,908 positions worth $164B, up 26% from $130B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Ken Griffin deployed $21.1B of net new capital in Q4 2017, opening 1,440 new positions and adding to 3,569 existing holdings. Its largest new stake was Celgene Corp: 3,708,916 shares worth $387M.
By sector, the portfolio is most concentrated in Technology at 6.2% of assets, down from 7.2% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Goldman Sachs, an estimated $441M trimmed.
- Ken Griffin's largest Q4 2017 buy was Celgene Corp: 3,708,916 shares worth $387M.
- Ken Griffin added most to State Street SPDR S&P 500 ETF Trust in Q4 2017, an estimated $1.16B increase.
- Ken Griffin's biggest Q4 2017 reduction was Goldman Sachs, cutting an estimated $441M.
- Ken Griffin fully exited CR Bard Inc. in Q4 2017, selling an estimated $209M.
- Ken Griffin's ten largest holdings make up 19% of its $164B portfolio in Q4 2017.
- Ken Griffin opened 1,440 new positions and closed 988 in Q4 2017.
- Ken Griffin's portfolio value rose 26% quarter-over-quarter to $164B.
Based on Citadel Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.